Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has administered the first human dose of HG-CT-1, its proprietary CAR-T cell therapy, to a patient with relapsed or refractory acute myeloid leukemia (R/R AML).

This milestone represents a significant step in the company's clinical development program, aimed at addressing the unmet needs of AML patients with limited treatment options.

Further updates on the trial will be shared as the study progresses.

Hemogenyx Pharmaceuticals is based in London and operates through its US subsidiaries Hemogenyx Pharmaceuticals LLC and Immugenyx LLC in New York City. The company is focused on developing innovative therapies for blood and autoimmune diseases, alongside advancing bone marrow transplantation options for patients with life-threatening conditions.